A mathematical model for targeting chemicals to tissues by exploiting complex degradation by Gardiner, Bruce et al.
RESEARCH Open Access
A mathematical model for targeting chemicals to
tissues by exploiting complex degradation
Bruce S Gardiner1*, Lihai Zhang2, David W Smith1*, Peter Pivonka1 and Alan J Grodzinsky3
Abstract
Background: In many biological and therapeutic contexts, it is highly desirable to target a chemical specifically to
a particular tissue where it exerts its biological effect. In this paper, we present a simple, generic, mathematical
model that elucidates a general method for targeting a chemical to particular tissues. The model consists of
coupled reaction-diffusion equations to describe the evolution within the tissue of the concentrations of three
chemical species: a (concentration of free chemical), b (binding protein) and their complex, c (chemical bound to
binding protein). We assume that all species are free to diffuse, and that a and b undergo a reversible reaction to
form c. In addition, the complex, c, can be broken down by a process (e.g. an enzyme in the tissue) that results in
the release of the chemical, a, which is then free to exert its biological action.
Results: For simplicity, we consider a one-dimensional geometry. In the special case where the rate of complex
formation is small (compared to the diffusion timescale of the species within the tissue) the system can be solved
analytically. This analytic solution allows us to show how the concentration of free chemical, a, in the tissue can be
increased over the concentration of free chemical at the tissue boundary. We show that, under certain conditions,
the maximum concentration of a can occur at the centre of the tissue, and give an upper bound on this
maximum level. Numerical simulations are then used to determine how the behaviour of the system changes
when the assumption of negligible complex formation rate is relaxed.
Conclusions: We have shown, using our mathematical model, how complex degradation can potentially be
exploited to target a chemical to a particular tissue, and how the level of the active chemical depends on factors
such as the diffusion coefficients and degradation/production rates of each species. The biological significance of
these results in terms of potential applications in cartilage tissue engineering and chemotherapy is discussed. In
particular, we believe these results may be of use in determining the most promising prodrug candidates.
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Background
A fundamental problem in biology and medicine is how
to target a chemical to the particular tissue where it is
to exert its biological action. Examples of chemicals to
be targeted include endogenous hormones, growth fac-
tors and prescribed drugs. The advantage of targeting a
drug to a particular tissue is that potential side-effects
of the undesirable presence of the drug in other tissues
are minimised.
The results of a previous theoretical study describing
the transport of IGF suggested a means of achieving
selective targeting to particular tissues. Selective degra-
dation of the IGF-IGFBP complex was shown to be cap-
able of regulating the free concentration of IGF (the
biologically active form) within a tissue. In some cases
the free IGF concentration in the tissue was raised to a
level an order of magnitude or more greater than in the
adjacent synovial fluid [1]. We believe that adjusting the
rate of degradation of the complex may well provide a
generic mechanism for tuning tissue exposure to various
chemicals in the body.
In order to gain further insight into these processes, in
this paper we perform a parametric study on a generic
system consisting of two molecules and their complex
diffusing within a tissue. We use a combination of
mathematical analysis and numerical simulations to
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conduct ‘mathematical experiments’ to investigate the
effect of the diffusion coefficients, degradation rates,
binding affinities, etc. on the uptake of molecules. Con-
sistent with the previous study of [1], the transport of
IGF, IGFBP and their small complex in cartilage are
considered. We also apply our model to the transport of
a prodrug within a tumour, which provides another
important illustration of this effect.
The primary source of circulating IGF-1 is the liver
and its serum concentration is relatively constant
throughout the day in healthy adults [2,3]. The interac-
tions between IGFs and several high-affinity IGF-binding
proteins (IGFBPs) are important for IGF transport [4-6]
from the liver to its site of biological action. In solution,
binding proteins (IGF-BPs) act as ‘carrier proteins’,
forming IGF-IGFBP complexes, which prolong the half-
life of IGFs [7]. For example, in serum the majority of
IGF-1 is bound to IGFBP3 [8]. Our recent theoretical
study investigated the role that diffusible binding part-
ners may play in regulating transport in a tissue [1].
Compared to the absence of a binding partner, it was
shown that the existence of a complex which is broken
down within the tissue, releasing free IGF, may lead to a
substantial increase in the free IGF concentration within
the tissue, even to concentrations well above those at
the tissue boundary. Such a mechanism is biologically
plausible as IGFBP-degrading proteases, such as matrix
metalloproteases (MMPs), are capable of cleaving IGFBP
into fragments that have a low binding affinity for IGFs,
releasing functional free IGF from the complex [5,9].
However, there are numerous other examples where
this mechanism for targeting a chemical to a particular
tissue can be exploited, particularly in drug delivery e.g.
of chemotherapeutic agents to solid tumours. To be
effective, the drug must be able to reach the tumour in
sufficient concentrations to kill the malignant cells, but
it is desirable to minimise exposure of healthy cells to
the drug, as it may cause tissue damage or lead to other
adverse side effects. Some treatments may be targeted
by injection directly into the tumour, but most current
types of chemotherapy are administered intravenously,
or orally, and so must reach their target via the circula-
tory system [10]. This route exposes healthy and malig-
nant cells alike to the drug. The problem is exacerbated
by the fact that solid tumours frequently contain poorly
vascularised regions, which means the drug must travel
further from the blood vessel to reach its site of biologi-
cal action. Further, advective transport with the intersti-
tial fluid may be reduced as a consequence of leaky
vessels within the tumour raising interstitial fluid pres-
sure [10]. These factors, together with the fact that the
drug is consumed within the tissue, means that those
areas furthest from the blood vessel generally receive
the lowest dose.
To overcome these difficulties, a variety of approaches
are being pursued to increase the concentration of the
drug within the tumour, including magnetic targeting
(which appears best suited to tumours near the surface
of the body) [11,12], or the use of macrophages
attracted to hypoxic regions as vehicles for drug delivery
[13]. However, some chemotherapeutic agents take the
form of a prodrug, which is administered in an inactive
form and subsequently metabolised to an active form in
the body. Experimental prodrugs (including tirapaza-
mine (TPZ), AQ4N and PR-104) have been developed
which are reduced to a cyctotoxic form only under
hypoxic conditions, preventing a build-up of the active
drug in well-oxygenated cells [10,14]. In terms of our
model, we can view the prodrug as being a complex,
which is broken down into an active, cyctotoxic form,
and a by-product.
Existing mathematical models for the transport and
metabolism of the prodrug TPZ suggest that it does not
penetrate efficiently into the tumour tissue [15,16],
which appears puzzling in the light of some promising
pre-clinical and clinical results [10] (although some
negative results have also been reported recently [17]).
However, these past models do not contain equations to
describe the distribution of the active drug. Here, we
apply our model to the transport of a generic prodrug
within a tumour. Our analysis shows that the concentra-
tion profiles of the prodrug and its active form may be
dramatically different, and hence it is important to look
at both when considering the likely effectiveness of the
drug. This might at least partly to explain the apparent
paradox with regard to TPZ penetration. More gener-
ally, an improved theoretical understanding of the var-
ious factors that affect the ability of the prodrug to
target the tumour would allow for more rapid identifica-
tion of the characteristics of the most promising drug
candidates.
This paper is organised as follows: in Methods, we
present the model equations, which comprise a coupled
system of three reaction-diffusion equations for the con-
centrations of two chemicals and their complex. Model
predictions are presented in Results and Discussion. We
first consider the special case in which the rate of for-
mation of the complex within the tissue is small. Under
this assumption, we are able to solve the model analyti-
cally, which allows us to show explicitly how the con-
centrations of each species depend upon the various
parameters. In this case, we are able to show that, under
certain conditions on the parameters, the maximum
concentration of active chemical (IGF or active drug)
can occur in the centre of the tissue, and give an upper
bound for this concentration. We then present numeri-
cal simulations of the full model, showing how increas-
ing the complex formation rate affects the solutions.
Gardiner et al. Biology Direct 2011, 6:46
http://www.biology-direct.com/content/6/1/46
Page 2 of 16
The paper concludes with a summary of our main
results, and suggested directions for future research.
Methods
We develop a mathematical model of a simple generic
system in which three chemicals, a, b and c, react and
diffuse within a region of tissue, Ω. We assume a and b
can undergo a reversible reaction to form a complex, c,
the rates of association and dissociation being k+1 and k-
1. Both a and b are assumed to be removed from the
tissue at constant rates, a1 and a2, respectively. Note
that, throughout this paper, we use the term ‘removal’
to describe all processes which result in a particular spe-
cies being unable to participate in further interactions;
such processes can include degradation, consumption or
conversion to an inactive form. The complex may also
be broken down by a reaction which results in the
release of a, without a corresponding release of b (e.g.
an enzymatic reaction which degrades b within the com-
plex). This reaction occurs at a rate k-2. These reactions
are summarised diagrammatically in Figure 1.
We denote the concentrations of the three chemicals,
a, b and c at a position x Î Ω by A (x, t), B (x, t) and C
(x, t) (where t is time). Each chemical diffuses within
the tissue, with diffusion coefficients DA, DB and DC
respectively. Then, applying the law of mass action, we
obtain the following system of reaction-diffusion equa-
tions for the chemical concentrations
∂A
∂t
= DA∇2A − k+1AB + (k−1 + k−2)C − α1A, (1a)
∂B
∂t
= DB∇2B − k+1AB − α2B + k−1C, (1b)
∂C
∂t
= DC∇2C + k+1AB − (k−1 + k−2)C. (1c)
Initially, we assume the chemical concentrations are
given by
A(x, 0) = Ai(x), B(x, 0) = Bi(x), C(x, 0) = Ci(x),(2)
whilst on the tissue boundary we set
A = A∗, B = B∗, C = C∗ on ∂. (3)
In terms of the cartilage example, we view a as repre-
senting IGF, b as IGF binding protein 3 (IGFBP3), and c
as the small, IGF-IGFBP3 binary complex. Our model
thus represents a simplified version of models previously
presented in [1,18]. In terms of the prodrug example,
we take c to be the prodrug, whilst a represents the
active form of the drug, with its removal being inter-
preted as consumption by the tumour cells. In this
example, b does not play an active role in the
chemotherapy, and represents a by-product of the
reduction of the produg.
Nondimensionalisation
We nondimensionalise equations (1) as follows (with
tildes indicating dimensionless quantities)
x = Lx˜, t =
L2 t˜
DC
, A = A∗A˜, B = B∗B˜, C = C∗C˜.
where L is typical lengthscale of the tissue, and A*, B*
and C* are the concentrations of a, b and c, respectively,
at the tissue boundary. The timescale chosen is the
timescale for the complex, c, to diffuse through the
domain. The dimensionless equations are then (drop-
ping tildes)
∂A
∂t
= δA∇2A − λ1μAAB + λ2μAC − λ3A (4a)
∂B
∂t
= δB∇2B − λ1μBAB − λ4B + λ5C (4b)
∂C
∂t
= ∇2C + λ1AB − λ2C (4c)
where we have introduced the dimensionless para-
meters
λ1 =
L2k+1A∗B∗
C∗DC
, λ2 =
L2(k−1 + k−2)
DC
,
λ3 =
α1L2
DC
, λ4 =
α2L2
DC
, λ5 =
L2k−1C∗
B∗DC
,
δA =
DA
DC
, δB =
DB
DC
, μA =
C∗
A∗
, μB =
C∗
B∗
.
The li (i = 1, 2, ..., 5) represent the ratios of the time-
scale of complex diffusion to timescales of the various
reactions: l1 is the relative rate of complex formation;
l2 and l5 are the relative rates of complex breakdown
to yield a and b, and l3 and l4 are the dimensionless
rates of removal of a and b. The ratio of the diffusivities
of a and b compared to that of c are given by δA and δB
respectively, and μA and μB are the ratios of the concen-
tration of complex to the concentration of a and b at
the boundary.
The solutions of the model equations are presented in
the following section. In certain cases the model can be
simplified sufficiently to be solved in closed form. This
provides both validation of, and complementary insight
to, the numerical solutions of the full model.
Results and Discussion
For simplicity, we consider a one-dimensional geometry,
where the tissue is taken to occupy the region -1 ≤ x ≤
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1 and we assume the problem to be symmetric about x
= 0. This geometry was assumed in previous studies of
IGF transport in cartilage [1,18], and hence facillitates
comparison with earlier results. In terms of the prodrug
example, we could take it as being representative of a
microenvironment inside a tumour where there are
blood vessels located at x = -1 and x = 1 (see e.g. [19],
where a similar geometry was adopted). Note that our
assumption of symmetry about x = 0 allows us to
restrict our attention to 0 ≤ x ≤ 1, with the boundary
conditions (3) modified to
∂A
∂x
=
∂B
∂x
=
∂C
∂x
= 0 at x = 0, (5a)
A = B = C = 1 at x = 1. (5b)
We restrict our attention to the steady-state solutions
of the governing equations, since we are interested in
the long-term behaviour of the system. For the purposes
of the numerical simulations, we set
A(x, 0) = B(x,0) = C(x,0) = 1, (6)
which is the simplest choice consistent with the
boundary conditions (5).
Analysis for small complex formation rate (l1 ≪ 1)
We now make the further assumption that the dimen-
sionless rate of complex formation (l1) is small. For the
case of IGF, this appears plausible, since taking the
Figure 1 Diagrammatic representation of the reactions (1).
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parameter estimates from [1] (A* ~ 10-11 M, C* ~ 10-9
M, L ~ 10-1 cm and k+1 ~ 10
5 M-1 s-1) and assuming B*
to be of a similar order of magnitude to A*, and DC to
be of the order of magnitude of DA (DA ~ 10
-7 cm2 s-1,
again from [1]) gives l1 ~ 10-3. For prodrugs, we like-
wise believe the assumption to be plausible (though it is
not possible to give a quantitative estimate based on
data from the literature). Typically, the prodrug must be
converted to a radical to be active, and under well oxy-
genated conditions, the unpaired electron on the radical
is rapidly transferred to molecular oxygen, preventing
build-up of the active drug. In the hypoxic environment
of the tumour, however, this transfer cannot occur, so
the rate at which the prodrug is regenerated is much
lower [14]. Hence we expect the prodrug concentration
will be much higher than those of its breakdown pro-
ducts in the blood (so A* B*/C* will be small), whilst
the rate of prodrug re-formation in the hypoxic environ-
ment of the tumour will be slow (hence L2 k+1/DC will
also be small). Throughout this section, we thus take l1
≪ 1 in (4) (with all other parameters assumed O(1)).
This simplification allows us to solve the governing
equations analytically, which provides a clear insight
into how complex degradation affects the distribution of
the active chemical in the tissue. The effect of relaxing
this assumption is considered in the following section.
For subsequent convenience, we write the solutions as
the sum of steady state and time dependent parts, so
that
A = AT(x, t) + AS(x), B = BT(x, t) + BS(x),
C = CT(x, t) + CS(x).
Since any difference between the initial and steady
state chemical distributions will decay exponentially fast,
we confine our attention to the steady state solutions
here. We expand the steady state components as a
power series in the small parameter l1 so that
AS = A0(x) + λ1A1(x) + . . . , (7)
and similarly for BS and CS .
Substituting the above into the governing equations
(4) we find the leading-order solutions obey
δA
∂2A0
∂x2
+ λ2μAC0 − λ3A0 = 0, (8a)
δB
∂2B0
∂x2
− λ4B0 + λ5C0 = 0, (8b)
∂2C0
∂x2
− λ2C0 = 0. (8c)
(We note that the leading-order time-dependent solu-
tions can also be obtained analytically by straightforward
separation of variables and application of Sturm-Liou-
ville theory (see e.g. [20]). The solutions of (8) are given
by
A0 =
⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
(
1 +
μAλ2
δAλ2 − λ3
) cosh(√ λ3
δA
x)
cosh(
√
λ3
δA
)
− μAλ2
δAλ2 − λ3
cosh(
√
λ2x)
cosh(
√
λ2)
) if δAλ2 = λ3,(
1 +
μA
√
λ2 tanh(
√
λ2)
2δA
)
cosh(
√
λ2x)
cosh(
√
λ2)
−μA
√
λ2
2δA
x sinh(
√
λ2x)
cosh(
√
λ2)
if δAλ2 = λ3,
(9a)
B0 =
⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
[
1 +
λ5
(δBλ2 − λ4)
] cosh (√ λ4
δB
x
)
cosh
(√
λ4
δB
)
− λ5 cosh(
√
λ2x)
(δBλ2 − λ4) cosh(
√
λ2)
if δBλ2 = λ4,[
1 +
λ5
2δB
√
λ2
tanh
√
λ2
]
cosh
√
λ2x
cosh
√
λ2
− λ5
2δB
√
λ2
x sinh
√
λ2x
cosh
√
λ2
if δBλ2 = λ4,
(9b)
C0 =
cosh(
√
λ2x)
cosh(
√
λ2)
. (9c)
We begin by considering the case l1 = 0, for which
the steady solutions are given exactly by (9), in order to
investigate the effects of the other parameters. Since the
equations for A0 and B0 are similar in form, we focus
on the behaviour of the solutions for A0 and C0. We
begin by noting the following basic points. Firstly, in the
absence of reactions (li = 0, i = 1, 2, ... 5), A0 = B0 = C0
= 1 - i.e. the steady state solution is spatially uniform
and the concentrations are equal to their values at the
boundary. When there is no breakdown of the complex
to produce a and b (i.e. l2 = l5 = 0), A0 and B0 have a
minimum at x = 0, since they are depleted in the tissue
due to removal. Provided l2 > 0, C0 has a minimum at
x = 0, since it is only supplied at the boundary, but
breaks down throughout the tissue.
If the aim is to maximise the concentration of a
throughout the tissue, intuition suggests that we need to
reduce l3/δA to as small a value as possible (i.e. mini-
mise the rate of removal relative to the rate of diffusion
of a). Taking l3 = 0, it is then clear from equation (9a)
that the largest values of A0 will occur when l2 is large,
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(i.e. when the rate of complex breakdown is fast com-
pared to its rate of diffusion). Furthermore, the maxi-
mum value of AS occurs at x = 0, in the centre of the
tissue. In the limit l2 ® ∞, the maximum value of A0
® 1+ μA/δA, and is attained throughout most of the tis-
sue (except for within a thin boundary layer, of width
O(λ
− 12
2 ))
close to x = 1, where the concentration of a
falls to unity). Correspondingly, C0 ® 0 in most of the
tissue, except in the thin layer at the tissue’s edge. This
type of behaviour is illustrated in Figure 2. We note
that, in this case, the level of a in the tissue does not
depend upon the rate of complex breakdown (which is
rapid), but is limited only by the supply of c to the tis-
sue (which occurs by diffusion), and ‘escape’ of a at the
edge of the tissue. Hence increasing the supply of c,
either by increasing its concentration at the boundary,
or by increasing its diffusivity results in increased levels
of a within the tissue, as does reducing the diffusivity of
a (which reduces the amount lost at the boundary).
From the point of view of prodrug delivery to tumours,
looking only at the concentration profile for c might
lead us to think that the penetration of the prodrug is
very poor (C0 is only nonzero in a thin layer close to
the boundary). However, when the concentration plot of
the active drug (A0) is considered, we would expect the
prodrug treatment to be highly effective, as the active
drug concentration is high throughout most of the
tumour.
For O(1) values of l3 (i.e. where the rate of consump-
tion or removal of a is appreciable), we can observe
three general types of behaviour. For the purposes of
illustration, we set l2 = 50, l4 = l5 = 0, μA = μB = δA =
δB = 1 (recall that l1 = 0 throughout this section), and
vary l3. The results are plotted in Figure 3. For rela-
tively small values of l3, AS has a single maximum, in
the centre of the tissue. (Note it is straightforward to
show that if x = 0 is a maximum of A0, then A0 has no
other fixed points.) Conversely, for large values of l3, A0
has a single minimum at the centre of the tissue. At
intermediate values, we see the third type of behaviour:
A0 has two extrema - a minimum at x = 0 and a maxi-
mum somewhere else in the tissue.
In terms of prodrug treatment for tumours, the aim
would be to achieve the greatest possible level of active
drug in the centre of the tumour (i.e. to maximise A0
(0)). Figure 4 shows a plot of A0(0) for a range of values
of l2 and l3. As might be expected, the maximum con-
centration of a occurs when there is no consumption/
removal (l3 = 0) and the rate of breakdown of the com-
plex, c, is large. In this case we notice A0(0) ® 1 + μA/
δA = 2 - i.e. supply of c becomes the limiting factor.
We now consider how the behaviour illustrated above
changes when l1 ≠ 0. For small values of l1 (assuming
all other parameters are O (1)), we can determine the
effect of complex formation on the distributions of the
three chemicals by considering the next-order correction
terms A1, B1 and C1 in the expansion (7). The general
solutions are
A1 =A∗ cosh
(√
λ3
δA
x
)
+
6∑
j=1
Aj cosh θjx
+A7 cosh(2
√
λ2x) +A8 cosh(
√
λ2x),
(10a)
B1 = B∗ cosh
(√
λ4
δB
x
)
+
6∑
j=1
Bj cosh θjx
+B7 cosh(2
√
λ2x) + B8 + B9 cosh(
√
λ2x),
(10b)
C1 = C∗ cosh
√
λ2x +
6∑
j=1
Cj cosh(θjx) + C7 cosh(2
√
λ2x) + C8, (10c)
where the θi are given by:
θ1 =
√
λ3
δA
+
√
λ4
δB
, θ2 =
√
λ3
δA
−
√
λ4
δB
, (11a)
θ3 =
√
λ3
δA
+
√
λ2, θ4 =
√
λ3
δA
−
√
λ2, (11b)
θ5 =
√
λ4
δB
+
√
λ2, θ6 =
√
λ3
δB
−
√
λ2. (11c)
For the sake of concision, the full details of the solu-
tions, including coefficients Aj, Bj, Cjetc. are given in the
Appendix.
Plotting the above correction terms for a range of
parameter values, as illustrated in Figure 5, we observe
that in general the effect of small but non-zero l1 is
exactly what would be anticipated: a reduction in the
concentration of a throughout the tissue, with a corre-
sponding increase in the concentration of c. The effect
is greatest in the centre of the tissue.
Numerical simulations of the full model
For the sake of completeness, we now turn to the gen-
eral case where the parameter values are unrestricted,
which requires the model equations (4) to be solved
numerically, subject to the boundary and initial condi-
tions (5)-(6). We use a semi-implicit finite difference
method in Matlab. The solutions were verified by check-
ing the results for small values of l1 against the analyti-
cal results obtained in the previous section, and were
found to give excellent agreement (data not shown).
The simulations presented in this section use a timestep
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Figure 2 Plots of the steady state solutions A0 and C0 for varying values of l2 (see equation (9)). Other parameter values: l3 = 0, μA =
100, δA = 1. Although the concentration of the complex, c, declines rapidly away from the tissue boundary, the level of a is rapidly increasing.
Thus, for the prodrug example, apparently poor prodrug penetration into the tissue can, in fact, correspond to high levels of active drug in the
tissue, due to efficient conversion of the prodrug to active form.
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dt = 0.005 and a spatial step dx = 0.002, and were run
until the solution reached steady state.
As we saw in the previous section, increasing l1
reduces the the concentration of a within the tissue,
and correspondingly increases the level of c compared
to the l1 = 0 case. However, when the parameter values
are O (1), moderate increases in l1 do not make a great
difference to the qualitative behaviour of the solutions,
as we see from from Figure 6. It is necessary to increase
l1 by an order of magnitude to observe such a change -
e.g. as shown in Figure 6 for l1 = 20, it is now possible
for A to have a second fixed point when x = 0 is a max-
imum, in contrast to what was found in the previous
section, for l1 = 0. When the other parameters are not
O (1), A and B can be large, and small values of l1 can
make a significant difference to the concentrations e.g.
see Figure 7 (note that in this case, our small l1 analysis
is not valid, as that requires the other parameters to be
O (1)). But here it is important to note that the complex
formation term introduces significant coupling between
the solutions for A and B, so the binding partner now
plays a role in determining the concentration of a,
rather than simply being a passive product of complex
breakdown. For example, repeating the simulation of
Figure 7, but with increased l4 (the dimensionless rate
of removal of b) results in a decreased level of b and
hence an increased concentration of a (compare Figures
7 and 8). This is because there is now less b available to
‘tie up’ a by forming the complex. Hence, we would
suggest that to achieve a high concentration of a, it is
generally desirable that the binding partner should be
removed as rapidly as possible from the tissue.
Conclusions
In this study, we have considered a simple mathematical
model for the interplay of diffusion, degradation and
Figure 3 Plots of the steady state solutions A0 for various values of l3 (see equation (9a)). Other parameter values: l2 = 50, μA = δA = 1.
For small l3 the centre of the tissue (x = 0) has the highest concentration of a; as l3 increases, the maximum point moves towards the tissue’s
edge (x = 1), until for sufficiently large l3, the concentration is monotonically decreasing away from the boundary.
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complex formation and breakdown in the transport of
two chemical factors and their complex. Interactions
between these processes can produce behaviours very
different to what is possible when complex breakdown
does not occur. Theoretically it is clear that the key to
targeting one of these chemicals (a) to a particular tis-
sue (and specifically, to the centre of that tissue) is to
ensure the complex breakdown rate is large (whilst the
formation rate is small), and the removal rate of a is as
small as possible. In addition the boundary concentra-
tion and diffusivity of the complex relative to those of a
should also be as large as possible, and the removal rate
of the binding partner b should be large, so it does not
persist in the tissue and ‘tie up’ a by forming the com-
plex. In certain parameter regimes, it is not only possi-
ble to raise the concentration of a in the centre of the
tissue to a level much higher than that outside, but also
for the concentration of a to be maximised there. This
may be significant in terms of the treatment of hypoxic
regions of tumours (see below). More generally, varying
the rate of complex breakdown and the rate of removal
can give different concentration profiles for a in the tis-
sue. This might also conceivably be used to provide
positional information to regulate cell behaviour e.g.
during development.
The results presented here complement an earlier
modelling study which considered the transport of IGF,
IGFBP and their complex in cartilage [1]. We have
shown that, generally speaking, fast breakdown of the
complex enhances the level of IGF in the tissue. How-
ever, when the rate of breakdown becomes very fast, the
concentration of IGF is limited by the balance of com-
plex entering the tissue, and IGF leaving the tissue,
embodied in the parameter ratio μA/δA in our model. It
is suggested that tissues may exploit the processes con-
sidered here to ‘tune’ their exposure to various factors.
As our results show, this tuning could be effected by
adjusting the rate of complex breakdown, or the rate of
Figure 4 Plot showing A0(0) (see equation (9a)) for a range of values of l2 and l3 (with μA/δA = 1). Note that the largest values of A0(0)
are achieved when l3 = 0 (no removal/consumption of a) and l2 is large (rapid breakdown of c), in which case AS (0) ® 1 + μA/δA = 2. Hence
the highest levels of a at the centre of the tissue occur when the rate of complex breakdown (l2) is rapid, and the rate of consumption of a
(l3) is minimised.
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removal of a (e.g. through regulation of enzyme activity
or receptor concentration). (It appears less likely that
the tissue would be able to influence the diffusivities or
boundary concentrations of the chemicals, though
changes in extracellular tissue matrix density and com-
position may exert some effect.) Importantly, this
mechanism can give relatively uniform levels of a
through most of the tissue (as seen in Figure 2), which
may be necessary for maintaining tissue homeostasis (e.
g. for the prescence of a hormone or growth factor in a
tissue).
In the context of the development of prodrugs for
treating tumours, our results suggest that not only
might it be possible to increase the active drug concen-
tration in the tumour to levels far above those in the
circulation, the centre of the tumour, generally the most
hypoxic region, can be preferentially targeted. Compared
to some earlier models (e.g. [15,16]), which consist only
of a reaction-diffusion equation for the concentration of
prodrug, our model can provide new insights when
applied to prodrug transport. Our results show that the
distribution of the active drug may be very different
from that of the prodrug, and that considering only the
latter can be misleading. We have seen that low levels
of prodrug in the centre of a tumour do not necessarily
imply poor penetration. They may, in fact, be a very
positive sign, associated with high levels of active drug
in that region, due to complete conversion of the pro-
drug to active form. This may explain the promising
pre-clinical and clinical results of the prodrug TPZ
referred to in [10], despite previous modelling suggest-
ing it does not penetrate efficiently into the tumour
Figure 5 Plots showing the first-order correction terms A1 and
C1 for various parameter values (see equation (10)). Dashed
line: l2 = 5, l3 = 0.5, l4 = 0.2, μA = 1. Dot-dashed line: l2 = 2, l3 =
1.5, l4 = 0.2, μA = 1. Solid line: l2 = 1, l3 = 0.5, l4 = 0.2, μA = 5. In
all cases we take: l4 = 0.2, l5 = muB = δA = δB = 1
Figure 6 Plots of the steady state solutions for A and C .
Parameter values: l1 = 0 (solid), l1 = 2 (dash), l1 = 20 (dot-dash).
Other parameter values: l2 = 5, l3 = 0.5 l4 = l5 = μA = μB = δA =
δB = 1 in all cases. Increasing the rate of complex formation (l1)
leads to a reduction in A, and corresponding increase in C. We also
note A can now have a maximum at x = 0 and another extremum
in 0 <x < 1, in contrast to the l1 = 0 case.
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[15,16]. However, the rate of consumption of the active
drug has an important role in determining its concen-
tration profile: low rates are required for a high concen-
tration of the active drug at the tumour centre. Higher
rates of drug consumption drag the drug concentration
profile down. Indeed, very high consumption rates result
in the situation that occurs for conventional therapies,
where the active drug concentration declines rapidly
with distance from the blood vessel. At intermediate
consumption rates, the drug concentration in the
tumour is greatest at some point between the boundary
and the centre of the tumour using this model of drug
behaviour. Nevertheless, high consumption rates, say by
receptor-ligand binding so dragging down drug concen-
tration profiles, implies that the drug is actually doing
what it is suppose to. When combined with experiments
to determine the diffusion coefficients and reaction rates
of the various species (along the lines of those presented
in [15,16]), the theoretical results presented here may be
of assistance in determining which potential new pro-
drugs are most likely to be effective, by excluding those
e.g. for which the diffusivity is too low, the rate of
reduction to active form too slow, or the rate of con-
sumption of the active drug too great. Whilst more
complex scenarios for prodrug activation can be envi-
saged, we believe a strength of our generic model is that
it gives a useful insight into the fundamental principles
involved, whilst being simple enough to be understood
on an intuitive level. It can also provide a foundation for
the development of more detailed models to elucidate
more complicated situations as needed. More
Figure 7 Plots of the steady state solution for A and B .
Parameter values: l1 = 0 (solid), l1 = 0.01 (dash). Other parameter
values: l2 = 1 l3 = l4 = 0.5, l5 = 12, μA = 10, μB = 0.2, δA = 0.02, δB
= 0.1. In this case, since A and B are relatively large (B = O(101) in
both cases; data for not shown), small values of l1 can make a
significant difference to the concentration profile.
Figure 8 Plots of the steady state solutions for A and B .
Parameter values: l1 = 0 (solid), l1 = 0.01 (dash). Other parameter
values: l2 = 1, l3 = 0.5 l4 = 10, l5 = 12, μA = 10, μB = 0.2, δA =
0.02, δB = 0.1. Compared to Fig. 7, we observe that decreasing the
level of b (through increasing l4) increases the concentration of a,
since the rate of complex formation is reduced.
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speculatively, we believe our results suggest another
potential avenue for drug delivery. Where a naturally
occurring chemical and binding partner (interacting in
the way assumed in this paper) can be found in a tissue
of interest, a drug might be designed in such a way that
it forms a stable complex with the binding partner. The
drug could then ‘piggy-back’ on this native binding pro-
tein, to be released preferentially in the tissue of interest.
Reviewers’ comments
Reviewer’s Report 1
Dr Artem Novozhilov (nominated by Eugene V. Koonin)
Main Comments
In this manuscript the authors present a mathematical
model that simulate interaction and diffusion of three
chemicals. It is shown by means of analytical and
numerical investigation that there are such parameter
values that, given the initial and boundary conditions,
it is possible to observe the maximum concentration of
one of the chemical in the middle of the spatial
domain, which is supposed to represent a tissue. The
modeling results are discussed in terms of potential
applications in cartilage tissue engineering and che-
motherapy. In this review I would like to refrain from
discussing possible implications of the modeling results
with respect to, e.g., chemotherapy, and focus my cri-
tique on the mathematical analysis of the system of
three reaction-diffusion equations formulated in the
manuscript. In general, I would recommend the
authors to present their mathematical results in a
more coherent and exact form.
Here are my comments listed in no particular order.
1. The authors first state that they consider the
boundary conditions of the form A = A*, B = B*, C =
C* (Eq. (3) on page 3). On page 4 they state that “... our
assumption of symmetry about x = 0 allows us to
restrict our attention to 0 ≤ x ≤ 1 with the boundary
condition (3) modified to
∂A
∂x
=
∂B
∂x
=
∂C
∂x
= 0 at x = 0 at
x = 1” These are two different mathematical problems.
These problems can be proved to be equivalent only in
the case of identical initial conditions for x < 0 and x >
0, which is generally not supposed in the paper, or in
the case of identical asymptotical behavior of solutions
for x < 0 and x > 0, which is not proved in the manu-
script. Therefore the jump from the first problem to the
second one requires some discussion.
Response: We agree the wording of this section was not
sufficiently precise. We have re-worded this to: ‘... and we
assume the problem to be symmetric about x = 0.’ which
we hope makes our intention clear.
2. The authors should elaborate on why they suppose
that at the ends of the spatial domain all three chemi-
cals have fixed concentrations. It can be supposed that
one of the chemicals is targeted to the tissue; can we
assume the same about the other two chemicals?
Response: The assumption of constant levels of A, B
and C on the tissue boundary, although a simplification
is, we believe, reasonable for the following reasons.
Firstly, in the case of IGF (and some other hormones), its
levels in the blood remain fairly constant throughout the
day, as mentioned in the introduction. The binding part-
ner is also fairly constant throughout the day and so the
complex concentrations can also be reasonably approxi-
mated as constant. In the case of a drug treatment, we
believe our assumption is a reasonable approximation
for the levels in the blood when the prodrug is adminis-
tered intravenously over a relatively long period (e.g.
hours). It would also be reasonable for in vitro experi-
ments where the tissue is placed in a large stirred bath
of solution containing the treatment. Of course, in reality
there will be examples of growth factors and drug
administration regimes where temporal variation in the
concentrations at the boundary is important. However,
we wished to consider a simple, generic example here;
such effects could be studied in future work.
3. On page 4 the authors write (I copy the sentence
verbatim) “We restrict our attention to the steadystate
solutions of the governing equations, since we are inter-
ested in the long-term behaviour of the system, and any
different between the initial condition and the steady
state will decay [. . . ]” The long-term behavior of a
dynamical system is characterized by the type of attrac-
tor it tends to; the attractors can be steady states (both
spatially homogeneous and non-homogeneous), cycles
(periodic solutions) or chaotic. I don’t fully understand
why it is a priory possible to restrict the attention to
only one type of long-term behavior.
Response: We agree that in general several long-term
behaviours are possible in dynamical systems, with
steady states being just one example. However, physical
intuition would suggest in this case the system would set-
tle to a steady state, and in an applied paper of this nat-
ure, we do not feel a great deal would be gained by
establishing this by rigorous mathematical proof. We
note our intuition is borne out by numerical simulations.
4. The next quote from the text (page 4): “As a result,
the initial conditions are immaterial”. If there are, for
instance, two asymptotically stable steady states then the
initial conditions become important.
Response: We agree with the reviewer that when there
are two asymptotically stable steady states, initial condi-
tions are not immaterial, and we have revised the text
accordingly. From numerical simulations, however, we
have not been able to find more than one asymptotically
stable steady state in this case.
5. The authors state (Abstract) that “In the special
case where the rate of complex formation is small [. . . ]
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the system can be solved analytically.” Actually, the
authors solve the system analytically only in the case
when the rate of complex formation is zero. For this
parameter value the system is linear, and therefore the
steady-state solution can be written down in an explicit
analytical form. Even in this case, however, it is neces-
sary to prove that this steady state solution is stable to
study the longterm behavior of the system (numerical
experiments show that it is stable).
Response: We agree with the reviewer notes that, in
general, when studying the long-time behaviour of dyna-
mical systems it is important to identify which (if any)
steady states are stable. However, considering the multi-
disciplinary audience of this journal, we believe too
much technical mathematical content may be off-putting
to many readers. In the case l1 = 0, the steady-state
equations are linear and so their solution is unique. Of
course, this does not prove that the system will evolve to
this steady state, but given the simple processes involved,
physical intuition would lead us to expect this, and it is
borne out by the numerical simulations. We thus believe
our approach is reasonable, although lacking mathema-
tical rigour. We would argue similarly in the nonlinear
(l1 >0) case.
6. In the case when the rate of complex formation is
zero (l1 = 0) the authors show, using the explicit solu-
tion, that it is possible to have the maximum of concen-
tration at the left boundary. This conclusion is hardly
surprising because, in words, the following system is
considered: There is a constant inflow of the chemical
from the right boundary, this chemical diffuses and
degrades, and there is an impenetrable boundary at the
left side. If the chemical does not degrade with a high
rate it is clear that the concentration at the left bound-
ary will increase. This conclusion does not need any
explicit math. Therefore, it would be interesting to see
which other insights can be obtained with the help of
the suggested system of differential equations.
Response: The reviewer suggests that a verbal argu-
ment suffices to understand the fact that, when l1 = 0,
the active drug concentration can have a maximum at
the centre of the tissue. We agree, but would point out
that not all the results of the model, even in this simpler
case, may not be so clear on an intuitive level. For exam-
ple, the fact that the maximum drug concentration may
occur at a point intermediate between the centre and the
edge of the tissue. If such an observation was made
experimentally, we do not believe it would necessarily be
intuitively obvious that it could be produced by the sim-
ple mechanism outlined here. We also see there is a
maximum theoretically attainable active drug concentra-
tion (A* + DC C*/DA in dimensional terms), which again
might not be intuitively clear, and obviously has practi-
cal implications.
7. The authors argue that the found analytical solution
is very close, in case of small l1, to the steadystate solu-
tion observed in the numerical experiments. The agree-
ment, according to the text, is excellent, but they do not
show the data. Let me consider the following values of
the parameters: l1 = 0.1, l2 = 1, l3 = 0.5, l4 = 0.1, l5 =
12, μA = 10, μB = 0, δA = 0.01, δB = 0.1. Using the exact
formula (9a) from the text and the standard numerical
PDE solver, I obtain the following figure (Figure 9).
Here the blue line shows the exact solution for A0 (x)
of the corresponding linear system, the red line shows a
numerical solution for A (x) of the full nonlinear system
for large t. This figure gives a clear example that it is
dangerous to make any conclusions about the long-term
behavior of the nonlinear system using the exact solu-
tions of the approximate linear system. From a mathe-
matical standpoint it is only possible to state that the
solutions of two systems are ε-close on the times of
order O(1/ε) but nothing can be proved for t ® ∞. In
general, the authors should either not consider the exact
solution of the approximate linear system or specify the
parameter domain in which the linear approximation
works.
Response: We thank the reviewer for drawing our
attention to this point. As is stated in the section on the
analysis of the small l1 case, we need to assume that the
other parameters are O(1) for analysis to be valid, and
we have now reiterated this at the beginning of the
appendix. (In passing, we remark that in some cases, the
approximate, small-l1 solution gives good agreement
even when this assumption is violated; however, this can-
not be expected in general.) We note that in the case pre-
sented by the reviewer, the ratio μA/δA (which appears in
the equation for A) is O(103); hence the grouping l1 μA/
δA is not small, and we would not expect our analysis to
be valid. However, we have now included an example of
this type of behaviour (the new Figure 7) in the numeri-
cal results section, as it demonstrates the important
point that there are situations where a small value of l1
can nevertheless make a significant difference to the solu-
tion. For the cases where the other parameters are O(1),
we have compared our analysis with the numerics for
several cases. The agreement with the leading-order solu-
tion is generally reasonable, and improves with the
Figure 9 Numerical simulation provided by Reviewer 1.
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addition of the first order correction term. However, since
this does not really provide any new information to the
reader, the relevant plots are omitted.
Minor Comments
1. Page 2, second column. “. . . the drug must the. . . “
should be “. . . the drug must be.”
2. Page 3, second column. Why use indexes for the
initial conditions?
3. Page 5, second column. “. . . exactly by (8). . . “
should be “. . . exactly by (9).”
4. Page 6, second column. A missing number in “. . .
in the expansion ().”
5. The first reference I checked has a typo: the paper
by Zhang et al. was published in 2010, not in 2009.
Please check all the other references.
Response: We thank the reviewer for also pointing out
a number of smaller errors, which we have corrected
according to their suggestions, except for retaining the
subscript i for initial conditions, where we think the
intended meaning is clear.
Reviewer’s Report 2
Dr William Hlavacek
Main Comments
The authors present steady-state results, including ana-
lytical results, for a model consisting of three partial dif-
ferential equations for a system in which there is a
reversible bimolecular association reaction (A+B = C)
and one-dimensional diffusion of the chemical species
A, B and C. The analytical results are approximate and
obtained through a perturbative approach. The analyti-
cal expressions given by the authors are fairly compli-
cated, and it is unclear that these expressions provide
more insight than purely numerical results. The model
is simple, but the authors explain that models even sim-
pler in some respects have been considered in earlier
related work and that their study is relevant for under-
standing penetration of the activated form of a prodrug
into a solid tumor and for understanding growth factor
action in tissues. The report is well written. The insights
gained from analysis of the model seem somewhat
obvious. For example, the authors conclude from their
analysis that rapid clearance of the activated form of a
prodrug will decrease its effectiveness. I’m not sure any-
one would need a model to understand this point. Also,
it is unclear that any of the insights gained from the
analysis are actionable. For example, the authors suggest
a piggy-backing strategy for increasing drug penetration
but no concrete example is provided. Can the authors
provide more details about potential proteins that could
serve as carriers of drugs into solid tumors? In any case,
the results are purely theoretical. There is no demon-
stration that the results are useful in practice. There is
only limited discussion of parameter estimates.
Response: We thank the reviewer for their report. They
note that the fact that e.g. increasing the rate of active
drug clearance tends to reduce its concentration in the
tissue is intuitively clear. We agree, but would point out
that there are phenomena which can be observed in the
model which may not be so clear on an intuitive level.
For example, the fact that the maximum drug concentra-
tion may occur at a point intermediate between the cen-
tre and the edge of the tissue. If such an observation was
made experimentally, we do not believe it would necessa-
rily be intuitively obvious that it could be produced by
the simple mechanism outlined here. Of course, many
other processes may produce such concentration profiles,
and each case must be considered individually. However,
we believe in general it would be sensible to consider the
possibility of a scenario of the type we have suggested.
We also agree that the analytical expressions (which are
given for the sake of completeness) are somewhat compli-
cated, and in are best illustrated by plots as for the
numerical results. However, we believe they can give use-
ful information about the dependence of the solution on
the various parameters. For example, we see there is a
maximum theoretically attainable active drug concentra-
tion (A* + DC C*/DA in dimensional terms). This is
potentially useful practically, since if this level is below
that at which the drug is effective, alternative strategies
for drug delivery will need to be investigated. Similarly,
our model suggests a framework by which simple in vitro
experiments might be used to characterise which are the
most promising drug candidates for development by
measuring parameters such as their diffusion coefficients
and reaction rates: e.g. those with the smallest value of
l1 or l3 or largest l2 appear more likely to give rise to
effective treatments. We note the recent study announ-
cing negative results in a trial of TPZ in treating
advanced squamous cell carcinoma of the head and
neck, and have included a reference to this paper. How-
ever, the argument we wished to make in our paper was
a general one: that considering merely the concentration
of the prodrug (C in our model) could be misleading,
since the concentration profile of the active drug (A) in
the tissue could be very different. This applies to any
drug which is delivered in the manner considered here.
Owing to lack of experimental data, we cannot make
any definitive statements about the effectiveness of TPZ,
and the reference to it was merely offered as a possible
example. We have re-written this paragraph of the
‘Background’ section to try to make our intention clearer.
Reviewer’s Report 3
Dr James Faeder
Main Comments
This paper presents a simple mathematical model to
describe the spatial distribution of drug in tissue where
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the drug may interact with another molecule (e.g. pro-
tein) to form a complex that undergoes degradation at a
different rate from the drug alone, producing back again
the active drug and eliminating the binding partner. The
appropriate partial differential equations to describe this
system in the continuum limit are derived and solved
exactly or approximately in limiting cases, and these
solutions are supplemented by the use of numerical
simulation on the full model. The main findings are that
under appropriate conditions, e.g., when the degradation
of active drug is relatively slow, the breakdown of the
complex is fast, and the rate of complex formation is
slow relative to the diffusion constant of the drug, the
concentration profile of the drug in tissue reaches a
maximum at the point farthest away from the bound-
aries (under the assumption of fixed concentrations on
the boundaries and a symmetric, 1D tissue). Such a pro-
file suggests a potential novel mechanism for the activity
of a drug that must be targeted selectively to a tissue by
utilizing enhanced tissue-specific degradation of a com-
plex between the drug and another molecule or protein.
Alternatively, some other tissue-specific factor, such as
hypoxia in the case of a tumor, may be used for rate-
enhancement of the activating process. I found this
paper to be very clearly written both at a general and
technical level. The findings are also clearly significant,
both for their potential therapeutic implications and for
modelers interested in applying this model or extensions
of it to model other systems. I have major criticisms of
the paper. - At the bottom of 2nd column on p. 3., I
found the sentence “In this example, b does not play an
active role. . . “ to be confusing. I think it would help to
explain the application of the model to the prodrug
example a bit more clearly. Specifically, how is b mod-
eled in that case?
-There is a typo in Eq. 8c, which is missing ‘=0’ before
the period.
Response: We thank the reviewer for their positive
report. We have addressed the minor matters raised in
the review.
A Details of the solutions for A1, B1 and C1 given
in equation (10)
For the sake of completeness, we give here the details of
the solutions for the first-order correction terms (note
that we assume that the other parameters, apart from l1
are O(1)). Substituting the expansions (7) into the gov-
erning equations (4), at O(l1), we find
∂2A1
∂x2
− μA
δA
A0B0 +
λ2μA
δA
C1 − λ3
δA
A1 = 0,
∂2B1
∂x2
− μB
δB
A0B0 − λ4
δB
B1 +
λ5
δB
C1 = 0,
∂2C1
∂x2
+ A0B0 − λ2C1.
The above are to be solved subject to the boundary
conditions
∂A1
∂x
=
∂B1
∂x
=
∂C1
∂x
= 0 at x = 0,
A1 = B1 = C1 = 0 at x = 1.
The general form of the solution to the above is given
by (10), whilst the details of the coefficients are provided
below. The Aj and A∗ are
Aj = −μACj
δA
(
θ2j − λ3δA
) for i = 1, . . . , 6,
A7 = −4λ2μAC7
δA
(
4λ2 − λ3δA
) , A8 = −μAλ2C∗
δA
(
λ2 − λ3δA
) ,
A∗ = − 1
cosh
√
λ3
δA
⎛
⎝ 6∑
j=1
Aj cosh θj +A7 cosh 2
√
λ2 +A8 cosh(
√
λ2x)
⎞
⎠
where the θj are given by equation (11), and the coeffi-
cients Cj and C∗ are given below.
The coefficients in the expression for B1 are given by
B1 = 1
δB
(
θ21 − λ4δB
) (μBβ1β3
2
− λ5C1
)
,
B2 = 1
δB
(
θ22 − λ4δB
) (μBβ1β3
2
− λ5C2
)
,
B3 = 1
δB
(
θ23 − λ4δB
) (μBβ1β4
2
− λ5C3
)
,
B4 = 1
δB
(
θ24 − λ4δB
) (μBβ1β4
2
− λ5C4
)
,
B5 = 1
δB
(
θ25 − λ4δB
) (μBβ2β3
2
− λ5C5
)
,
B6 = 1
δB
(
θ26 − λ4δB
) (μBβ2β3
2
− λ5C6
)
,
B7 = 1
δB
(
4λ2 − λ4δB
) (μBβ2β4
2
− λ5C7
)
,
B8 = 1
λ4
(−μBβ2β4
2
+ C8
)
, B9 = − λ5C
∗
δB
(
λ2 − λ4δB
) ,
B∗ = − 1
cosh
√
λ3
δA
⎛
⎝ 6∑
j=1
Bj cosh θj + B7 cosh 2
√
λ2 + B8 + B9 cosh(
√
λ2x)
⎞
⎠ ,
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where we have introduced
β1 =
1
cosh
√
λ3
δA
(
1 +
λ2μA
δAλ2 − λ3
)
,
β2 = − 1
cosh
√
λ2
(
λ2μA
δAλ2 − λ3
)
,
β3 =
1
cosh
√
λ4
δB
(
1 +
λ5
δBλ2 − λ4
)
,
β4 = − 1
cosh
√
λ2
(
λ5
δBλ2 − λ4
)
.
Finally, the coefficients in the solution for C1 are
C1 = − β1β3
2(θ21 − λ2)
, C2 = − β1β3
2(θ22 − λ2)
,
C3 = − β1β4
2(θ23 − λ2)
, C4 = − β1β4
2(θ24 − λ2)
,
C5 = − β2β3
2(θ25 − λ2)
, C6 = − β2β3
2(θ26 − λ2)
,
C7 = −β2β46λ2 , C8 =
β2β4
2λ2
,
C∗ = − 1
cosh
√
λ2
⎛
⎝ 6∑
j=1
Cj cosh θj + C7 cosh 2
√
λ2 + C8
⎞
⎠ .
We note, as is clear from the above, that the solution
(10) is only valid provided θ2i = λ3δAetc.; however, the solu-
tions in the special cases where this doesn not apply can
be found from (10) by straightforward application of
L’Hopital’s rule.
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